-+ 0.00%
-+ 0.00%
-+ 0.00%

Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar

MT Newswires·12/23/2025 10:14:26
Listen to the news
10:14 AM EST, 12/23/2025 (MT Newswires) -- Formycon (FYB.F) secured the US Food and Drug Administration's approval for Nufymco, its interchangeable biosimilar to Lucentis, for use in treating age-related neovascular macular degeneration and other serious eye conditions. Zydus Lifesciences will be the German biosimilar developer's commercialization partner in the US for the newly approved biosimilar, according to a Tuesday release.